Greenland Mines Ltd. (Nasdaq: GRML)
NEWS
Greenland Mines And Its Subsidiary Major Precious Greenland A/S Join the European Raw Materials Alliance
CHARLOTTE, N.C., May 5, 2026 /PRNewswire/ — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML) is pleased to announce that the Company and its 80%-owned Greenland subsidiary Major Precious Greenland A/S have become members of the European Raw Materials Alliance (“ERMA”), an industry‑driven alliance established by the European Commission to help secure reliable, secure and sustainable access to critical and strategic raw materials for Europe’s industrial ecosystems.
ERMA, managed by EIT RawMaterials, brings together stakeholders from across the raw‑materials value chain – including mining and exploration companies, processing and recycling firms, OEMs, technology providers, research organisations, investors, regions and NGOs – to identify investment cases, remove barriers, and support the development of resilient, low‑carbon supply chains for critical raw materials, advanced materials and processing know‑how. The alliance plays a central role in implementing the EU’s Action Plan on Critical Raw Materials and supports emerging initiatives under the new EU Critical Raw Materials Act.
Bo Møller Stensgaard, Ph.D., Greenland Mines Ltd President, commented: “Joining the European Raw Materials Alliance with both Greenland Mines and Major Precious Greenland A/S is an important step in positioning Skaergaard where it belongs: at the heart of the European, North American and transatlantic discussion on secure, low‑carbon critical‑raw‑materials supply. ERMA is the central industrial ecosystem for critical raw materials in Europe, and we are pleased to now be part of that community as we advance Skaergaard.
“Our strategy is to build a North Atlantic critical‑minerals corridor that links world‑class geology in Greenland, developed by Greenland Mines, with potential low‑carbon processing in Iceland and direct access to both European and North American markets. ERMA provides an ideal platform to discuss this concept with industrial end‑users, technology partners and policymakers, and to explore how Skaergaard can fit into future transatlantic supply and value chains.”
While EU Strategic Mineral Project designations under the EU Critical Raw Materials Act are decided by the European Commission through a formal application process, ERMA serves as an investment pipeline and support platform for high‑potential raw‑materials projects aligned with those objectives, helping to identify and mature investment cases across the value chain.
Aligning Skaergaard with Europe’s critical raw‑materials agenda
Membership in ERMA positions the Skaergaard Gold, Palladium, Platinum and Critical Metals Project squarely within the European conversation on critical‑raw‑materials security, value‑chain resilience and industrial competitiveness. ERMA’s stated objectives include:
- Diversifying Europe’s supply of critical and strategic raw materials from both primary and secondary sources
- Identifying and supporting investment projects along the full value chain, from mining and processing to recycling and circular‑economy solutions
- Creating industrial clusters and partnerships that can accelerate project development and deployment
For Greenland Mines, ERMA membership provides a structured platform to:
- Engage directly with European industrial users in sectors such as automotive, energy, defence, aerospace and high‑tech manufacturing, where PGMs and other Skaergaard metals play key roles
- Explore options for strategic partnerships, offtake frameworks and co‑investment concepts that can support the advancement and de‑risking of the Skaergaard Project
- Contribute to broader discussions on how Greenland and the wider North Atlantic region can support Europe’s critical‑raw‑materials and climate objectives
ERMA has already shown its willingness to support high‑potential raw‑materials projects in Greenland. Greenland Mines’ membership builds on this emerging track record of Greenland‑EU collaboration in raw materials.
Connecting to the North Atlantic critical‑minerals corridor
The Company’s entry into ERMA complements its recently announced North Atlantic Processing Site Strategy, under which Skaergaard ore would be mined and pre‑processed in East Greenland and then potentially shipped a short distance to Iceland for low‑carbon, geothermal‑powered downstream processing, forming the backbone of a prospective North Atlantic Critical Metals corridor.
By combining a large, multi‑metal resource base in Greenland with a potential low‑carbon processing hub in Iceland and participation in ERMA’s EU‑centred industrial ecosystem, Greenland Mines is positioning Skaergaard as a strategic project for both Europe and North America with the ability to contribute to secure, resilient and transparent raw‑materials supply chains across the Atlantic.
Although Greenland Mines is a US‑registered, Nasdaq‑listed company, the addition of ERMA membership – alongside the Company’s membership of the Greenland Business Association through Major Precious Greenland A/S – highlights its commitment to working within and across both European and North American frameworks to unlock the full potential of Skaergaard in a way that aligns with allied climate, security and industrial‑policy objectives.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq, respectively The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
https://edge.prnewswire.com/c/img/favicon.png?sn=LA51100&sd=2026-05-05 View original content to download multimedia:https://www.prnewswire.com/news-releases/greenland-mines-and-its-subsidiary-major-precious-greenland-as-join-the-european-raw-materials-alliance-302762153.html
SOURCE Greenland Mines Ltd
Greenland Mines (NASDAQ:GRML) Signs 12-Part Featured Series on New to The Street
The series includes earned media, NewsOut press release coverage, TV commercials, outdoor billboards, and accredited investor events for comprehensive market support.
NEW YORK CITY, NY / ACCESS Newswire / May 4, 2026 / New to The Street, one of the longest-running business television brands broadcasting as sponsored programming on Bloomberg Television and Fox Business, today announced that Greenland Mines (NASDAQ;GRML) has signed a 12-part featured series designed to elevate its visibility across national television, digital platforms, and investor-focused channels.
The multi-part series will feature in-depth, long-form interviews with company leadership, providing a platform to communicate Greenland Mines’ business model, strategic initiatives, and market positioning to a broad audience of retail and institutional investors. Each segment will air nationwide on Bloomberg Television and Fox Business, with additional distribution across New to The Street’s expanding digital ecosystem.
As part of the agreement, Greenland Mines will receive a fully integrated media package that includes earned media placements, NewsOut video press release coverage, professionally produced TV commercials, and high-impact outdoor billboard campaigns in iconic financial districts, including Times Square, New York City. The program also includes participation in accredited investor events, offering direct engagement with a curated audience of investors and financial professionals.
“This 12-part series reflects our continued commitment to delivering meaningful exposure and narrative-driven storytelling for innovative public companies,” said Vince Caruso, Co-Founder of New to The Street. “By combining national television, digital amplification, and outdoor media, we create a unified platform that ensures our clients’ stories are not only told-but seen and engaged with at scale.”
Greenland Mines will also benefit from New to The Street’s powerful digital distribution network, including its flagship YouTube channel (https://youtube.com/@newtothestreettv?si=sXEzZM8rlD9o9YTz) and the NewsOut platform (https://youtube.com/@newsoutchannel?si=_lFvv3AtDo9v-t-h), which together reach over 5.4 million combined subscribers. When integrated with the In$ane Influencers platform, the total audience expands to over 6.5 million subscribers, delivering amplified visibility and sustained engagement across multiple investor touchpoints.
The series is expected to begin filming immediately, with the first broadcast scheduled in the coming weeks.
About New to The Street
New to The Street is a premier business television platform that showcases public and private companies through long-form interviews and multi-channel media distribution. Broadcasting weekly as sponsored programming on Bloomberg Television and Fox Business, the brand reaches millions of households across the United States, as well as audiences in MENA and Latin America. In addition to its television presence, New to The Street delivers integrated media solutions including earned media, digital distribution, social amplification, and outdoor advertising in key financial markets.
Media Contact:
Monica Brennan
Monica@NewtoTheStreet.com
To Be Featured / Investor Inquiries:
John@NewtoTheStreet.com
SOURCE: New to The Street
View the original press release on ACCESS Newswire
https://app.accessnewswire.com/img.ashx?id=1163360
© Copyright 2026 ACCESS Newswire. All Rights Reserved.
Greenland Mines (NASDAQ: GRML) Locks In World-Class Technical Team for $68B Skaergaard PGM-Gold Deposit as Western Critical Minerals Push Accelerates
Issued on behalf of Greenland Mines Ltd
SECTOR INTELLIGENCE BRIEF | In five weeks, Greenland Mines has assembled SLR Consulting (geological / Qualified Person), GTK Mintec (metallurgy and pilot processing), and WSP (environmental baseline) around its Skaergaard Project — one of the world’s largest undeveloped palladium-gold-platinum deposits — while signing a Letter of Intent for a downstream processing hub in Iceland targeting power costs below $0.03/kWh.
CHARLOTTE, N.C., April 30, 2026 (GLOBE NEWSWIRE) — World Street Intelligence News Commentary — A series of rapid-cadence corporate developments at Greenland Mines Ltd (Nasdaq: GRML) over the past five weeks has positioned the Company at the intersection of two of the most consequential macro narratives in mining: structural undersupply across the platinum group metals (PGM) complex, and a Western governmental push to onshore and de-Sino-fy critical minerals supply chains. The Company’s flagship Skaergaard Project in Southeast Greenland hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz palladium-equivalent and 23.5 Moz gold-equivalent, with a gross undiscounted in-situ resource value of approximately $68 billion at February 2026 metal prices.
KEY TAKEAWAYS
|
RESOURCE SCALE
A $68 Billion In-Situ Resource Anchored in Major-Discovery Geology
According to the Company’s public disclosures, Skaergaard hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 million ounces palladium-equivalent and 23.5 million ounces gold-equivalent. The gross undiscounted in-situ resource value, calculated using February 2026 metal prices and assuming 50% gold / 50% PGMs, is approximately $68 billion. The deposit ranks among the largest undeveloped palladium-gold-platinum deposits in the world.
Greenland Mines holds an 80% direct interest in the Skaergaard Project — acquired through Greenland Mines Corp. — together with an option to acquire the remaining 20%. The mineralization is hosted across seven defined stratiform horizons (H0-H6) within the Skaergaard intrusion, an Eocene-age layered mafic intrusion (Triple Group) that has been the subject of academic and exploration-stage investigation since the 1990s, with approximately $30 million of historical exploration investment.
No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on Skaergaard. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values referenced above are illustrative calculations and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors.
TECHNICAL DE-RISKING CADENCE
Five Weeks. Three World-Class Consultants. One Integrated Technical Foundation.
Most junior mining developers spend years assembling the kind of consulting team Greenland Mines has put in place since mid-March. The cadence reads as follows:
WSP Denmark (engaged March): Full environmental impact assessment (EIA) baseline program at Skaergaard, the foundational regulatory work product required for project advancement under Greenlandic mining law.
GTK Mintec framework (Apr 23): Multi-stage metallurgical and processing flow program executed at GTK Mintec — the mineral processing and circular-economy pilot plant of the Geological Survey of Finland (GTK) located in Outokumpu, Finland. The facility runs approximately 100 projects per year and 8–12 industrial-scale pilot runs annually. Scope includes advanced mineralogical characterization (MLA / QEMSCAN, EPMA), gold deportment, beneficiation testwork, hydrometallurgical testwork (chloride leaching, pressure oxidation, Kell-type, molten-salt processes), and pilot-scale processing using a 10-20 tonne bulk sample. Tailings and extractive-waste studies will be conducted on the SMARTTEST platform.
SLR Consulting (Apr 27): Appointed as Geological Consultant and Qualified Person for Skaergaard. SLR — with more than 5,000 employees across 140+ offices worldwide — is the same consulting firm that prepared the latest NI 43-101 Technical Report effective November 22, 2022, including the current Mineral Resource Estimate. SLR specialists are scheduled for a return site visit in late August or early September 2026 in connection with the Company’s planned summer field program.
Greenland Mines President Bo Møller Stensgaard, Ph.D., framed the integration in the SLR announcement: “We believe this gives Skaergaard a particularly strong and integrated technical foundation as we move into the 2026 field season and as we continue to systematically unlock the full potential of Skaergaard.”
NORTH ATLANTIC CRITICAL-MINERALS CORRIDOR
Mine in Greenland. Process in Iceland. Sub-$0.03/kWh Power.
On April 16, 2026, Greenland Mines announced a non-binding Letter of Intent with an Icelandic industrial site owner to evaluate a downstream processing hub. The strategic logic is structural rather than incremental: Skaergaard sits approximately 450 km west of Iceland — within direct reach of one of the lowest-cost industrial-power jurisdictions in the developed world.
According to the announcement, the LOI targets power costs potentially below US$0.03/kWh through Iceland’s integrated geothermal and hydropower grid, with life-of-mine savings exceeding $1 billion against alternative on-site processing scenarios. The brownfield refurbishment approach uses existing buildings, deep-water harbor infrastructure, and grid connections — meaningfully reducing capital intensity versus greenfield development.
The Company has framed this configuration as a “North Atlantic critical-minerals corridor” — connecting Greenland resource development to North American and European refining markets through low-cost Icelandic processing. The framing aligns with the broader strategic Western response to critical-minerals supply concentration risk, which currently sees Russia accounting for approximately 40% of global palladium supply and South Africa accounting for approximately 75% of global platinum supply.
PGM SUPPLY MACRO
A Structural Undersupply Story That Has the Major Banks Re-Rating Forecasts
In January 2026, Bank of America Global Research raised its 2026 platinum price forecast to $2,450/oz (from $1,825) and its palladium price forecast to $1,725/oz (from $1,525). The bank cited persistent market deficits, the dislocations of PGMs from trade disputes keeping markets tight, and Chinese demand support including the launch of physically-backed platinum and palladium futures contracts on the Guangzhou Futures Exchange (GFEX) in the second half of 2025.
On the supply side, the World Platinum Investment Council (WPIC) reports the platinum market entered a third consecutive year of supply deficit in 2025, with the shortfall estimated at approximately 850,000 ounces. The 2025 platinum price rallied approximately 127%. South African platinum output contracted approximately 5% year-on-year during January-October 2025, driven by operational issues including flooding and plant maintenance.
On the policy side, the U.S. Department of Commerce has estimated a dumping margin of approximately 828% on unworked Russian palladium imports following anti-dumping and countervailing duty petitions filed by Sibanye-Stillwater and the United Steelworkers Union. Any imposition of tariffs on currently-unspecified Russian volumes could push U.S. domestic prices materially higher and reshape import economics for North American and European markets.
CAPITAL CONTEXT
PGM and Precious Metals Producers — Comparable Set
Investors evaluating exposure to the PGM supply-deficit thesis have an identifiable U.S.-listed comparable set of producers and developers across the platinum group metals complex. Each has reported material newsflow within the past month tied to the same macro cycle that supports Greenland Mines’ positioning.
Sibanye-Stillwater Limited (NYSE: SBSW)
Sibanye-Stillwater is the diversified PGM and gold producer with operations across South Africa and the United States (Stillwater and East Boulder mines in Montana — host to the J-M Reef, the highest-grade PGM deposit in the world). The company has delivered approximately 295% one-year total return on surging precious metals prices and execution of its operational turnaround. FY2025 results showed revenue up 16% and adjusted EBITDA up 189% with margin expansion to 29.2%, despite non-cash impairment charges. Sibanye-Stillwater filed the petitions that triggered the U.S. Department of Commerce’s preliminary affirmative anti-dumping determination on Russian palladium imports announced in 2026.
Valterra Platinum Limited (OTC: ANGPY)
Valterra Platinum — formerly Anglo American Platinum, demerged from Anglo American plc on May 31, 2025 — is the world’s largest primary platinum producer, accounting for approximately 38% of global annual supply. The company reported FY2025 production of 3.2 million PGM ounces (M&C) and refined production of 3.4 million PGM ounces, both marginally above guidance. FY2025 sales volumes reached 3.5 million PGM ounces, including realization of refined inventory into a stronger PGM price environment. CEO Craig Miller framed FY2025 as “a defining year” with the successful demerger and London Stock Exchange secondary listing complete.
Platinum Group Metals Ltd. (NYSE American: PLG)
Platinum Group Metals operates the Waterberg Joint Venture in northeast South Africa, which holds 23,410,000 ounces of 4E Proven and Probable reserves comprising approximately 28.7% platinum, 63.5% palladium, and 6.2% gold. The Waterberg JV board unanimously approved ZAR 92.1 million in late 2025 for a sixth stage of work programs in fiscal 2026. With a modest share count of approximately 116 million shares outstanding, the stock has been characterized by technical analysts as offering meaningful percentage-gain potential as Waterberg advances toward production decisions.
Generation Mining Limited (OTCQB: GENMF / TSX: GENM)
Generation Mining is advancing the Marathon Copper-Palladium Project in northwestern Ontario, Canada — one of the few fully permitted critical mineral projects in North America. The Company’s 2024 Feasibility Study estimated a Net Present Value of C$1.07 billion (6% discount rate), Internal Rate of Return of 28%, and a 1.9-year payback, with a 13-year mine life producing approximately 2,161,000 ounces of palladium, 532 million pounds of copper, 488,000 ounces of platinum, 160,000 ounces of gold and 3,051,000 ounces of silver in payable metals. Total initial capital is approximately C$992 million (US$703 million). On January 15, 2026, the Company closed an upsized C$34.5 million bought-deal financing. On March 2, 2026, Generation Mining awarded the Engineering, Procurement and Construction Management contract to Ausenco, with field execution targeted for Q3/Q4 2026 subject to financing.
INVESTOR Q&A
Three Questions on the Greenland Mines Thesis
Q: What makes Skaergaard’s $68 billion in-situ resource value different from other large undeveloped PGM projects?
A: Three things at once: scale (25.4 Moz PdEq / 23.5 Moz AuEq across seven defined horizons), geological consistency in a Triple Group mafic layered intrusion measuring 7.5 km by 11 km, and multi-metal optionality including vanadium, gallium, germanium, and titanium recovery alongside the primary PGM-gold deposit. Most large undeveloped PGM projects offer one or two of those — Skaergaard offers all three. No PEA, PFS, or feasibility study has been completed.
Q: Why does the technical team assembled in five weeks de-risk the story materially?
A: SLR Consulting prepared the November 2022 NI 43-101 Technical Report and is now back as Qualified Person — removing the relearning curve. GTK Mintec brings industrial-scale pilot processing, and WSP delivers the environmental baseline required under Greenlandic mining law. Each engagement removes a specific technical or regulatory risk that would otherwise be priced into a junior mining valuation.
Q: How does the structural PGM supply deficit translate into a thesis for early-stage developers like Greenland Mines?
A: Bank of America raised its 2026 platinum forecast to $2,450/oz and palladium to $1,725/oz, citing persistent deficits and trade-policy dislocations — including an approximately 828% U.S. dumping margin on Russian palladium. As long-life PGM supply tightens in concentrated jurisdictions (Russia ~40% palladium, South Africa ~75% platinum), capital tends to rotate toward early-stage developers in Western-aligned jurisdictions with scale and a credible technical pathway. Early-stage developers carry execution and dilution risks that established producers do not.
BOTTOM LINE
A Differentiated Position in a Re-Rating PGM Cycle
The PGM supply-deficit thesis has moved from analyst forecast to bank price target revision. The Western critical-minerals onshoring push has moved from policy framing to direct equity investments. Russian palladium tariff risk has moved from petition to preliminary affirmative anti-dumping determination. Against that macro backdrop, Greenland Mines has compressed five weeks of technical and strategic announcements — SLR Consulting, GTK Mintec, WSP, Iceland LOI, Major Precious Greenland Business Association membership — into an integrated thesis that connects a $68 billion in-situ resource to a North Atlantic processing corridor with sub-$0.03/kWh power.
For investors evaluating exposure to the PGM cycle, the comparable set above (SBSW, ANGPY, PLG, GENMF) represents the established producer and developer cohort. Greenland Mines represents the early-stage Western jurisdiction component of the same cycle — a different angle on the same underlying spending and pricing dynamics.
For more information on Greenland Mines Ltd, visit www.greenlandmines.com or the investor profile at usanewsgroup.com/grml-profile/.
CONTACT:
USA News Group
(604) 265-2873
DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for World Street Intelligence on behalf of Creative Direct Marketing Group (“CDMG”) by Market IQ Media Group Inc. (“MIQ”). Regarding this publication, MIQ has been paid a fee for Greenland Mines, Inc. advertising and digital media from Creative Digital Media Group (“CDMG”). There may be 3rd parties who may have shares of Greenland Mines, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. The owner/operator of MIQ does not currently own shares of Greenland Mines, Inc. but reserves the right to buy and sell, and will buy and sell shares of Greenland Mines, Inc. at any time without any further notice commencing immediately and ongoing. This potential for trading constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this, individuals are strongly encouraged to not use this publication as the basis for any investment decision. Please let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been reviewed and approved on behalf of Greenland Mines, Inc. by CDMG.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
CAUTIONARY NOTE REGARDING MINERAL RESOURCES:
The Mineral Resource Estimates referenced in this article were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
FORWARD-LOOKING STATEMENTS:
This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward-looking statements in this publication include that demand for platinum group metals and critical minerals will continue to grow and tighten; that Greenland Mines Ltd’s Skaergaard Project will advance through its planned technical, metallurgical, and environmental work programs as described; that the Company’s engagements with SLR Consulting, GTK Mintec, and WSP will proceed as planned; that the Iceland LOI will progress toward a binding agreement with the cost and savings characteristics described; that comparable companies will perform as expected. The forward-looking information contained herein is provided for the purpose of assisting the reader to understand the Company’s business, however such information may not be appropriate for other purposes. Risks that could change or prevent these statements from coming to fruition include changing governmental laws and policies; permitting risks; the Company’s ability to obtain and retain necessary licensing; political and competitive risks; failure of forecasts and assumptions to come to fruition; metal price volatility; the inherent uncertainty of mineral resource estimates; and other unforeseen circumstances. The publisher of this article does not take responsibility for the accuracy of any statements made by the issuing company or its representatives. Readers are cautioned not to place undue reliance on these forward-looking statements, and the publisher undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.
https://www.globenewswire.com/newsroom/ti?nf=OTcxMDYyOCM3NTc2MDU3IzUwMDE2MTUzNw==
https://ml.globenewswire.com/media/ZDJiMmZmMmYtODNiNy00YTg2LTlhNWQtZTIxNjU4NmJhM2FiLTUwMDE2MTUzNy0yMDI2LTA0LTMwLWVu/tiny/World-Street-Intelligence.png
Source: World Street Intelligence
© 2026 GlobeNewswire, Inc.
Greenland Mines Appoints SLR Consulting as Geological Consultant and Qualified Person for Skaergaard
PR Newswire
CHARLOTTE, N.C., April 27, 2026 /PRNewswire/ — Greenland Mines Ltd (Nasdaq: GRML) (“Greenland Mines” or the “Company”) announces the appointment of SLR Consulting (“SLR”) as geological consultant and Qualified Person for the Company’s Skaergaard Project in East Greenland. The appointment further strengthens Greenland Mines’ technical platform as the Company advances Skaergaard through its next stage of work and continues to assemble a high-caliber team of specialist advisors across geology, metallurgy, mine engineering, environmental studies, and project development.
Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Bo Møller Stensgaard, Greenland Mines President, commented, “The appointment of SLR Consulting as geological consultant and Qualified Person for the Skaergaard Project provides a major advantage for Greenland Mines in that SLR already knows Skaergaard well through its earlier work on the Project, including the latest NI 43-101 Technical Report and the 2022 Mineral Resource Estimate.
“SLR is a highly respected international consultancy with deep technical capabilities and has assembled a strong team of specialists who can contribute across several important aspects of Skaergaard’s continued advancement. They will serve both as geological consultant and Qualified Person and also are expected to play a broader technical role in shaping the next phase of Skaergaard’s development. This includes support for mining operations definition, mining methods, mine planning, metallurgy, processing flowsheet development and mine engineering work, in coordination with GTK Mintec, WSP and the rest of the Greenland Mines technical team.
“We believe this gives Skaergaard a particularly strong and integrated technical foundation as we move into the 2026 field season and as we continue to systematically unlock the full potential of Skaergaard.”
SLR is a well-established international consultancy with a strong reputation across mining advisory, technical reporting, engineering, and sustainability services. SLR has more than 5,000 employees across more than 140 offices worldwide, while its mining advisory practice spans exploration, Mineral Resource and Mineral Reserve work, mine engineering, metallurgy, due diligence and technical studies across the mining lifecycle.
For Greenland Mines, the appointment is especially valuable because SLR already has direct familiarity with the Skaergaard Project. SLR Consulting Canada Ltd. prepared the latest NI 43-101 Technical Report on Skaergaard, effective November 22, 2022, including reporting of the current Mineral Resource Estimate.
The Company believes that SLR’s prior involvement, previous site visits and established understanding of geology and mineralization, as well as the recent and historical amount of data and project setting, will support efficient execution and strong technical continuity as work progresses.
Under the current framework, SLR will support Greenland Mines across a broad range of geological, technical and project-advancement activities, including resource definition-related work, drill and bulk-sample planning, project database development, mining and development roadmap work, and input into mining methods, mine planning, metallurgy, processing flowsheet definition and mine engineering studies intended to help advance Skaergaard toward future technical milestones. The agreement also contemplates a return site visit by SLR specialists in late August or early September 2026 in connection with the Company’s planned summer field activities.
Greenland Mines also expects SLR to work closely with the other leading consultants already engaged on the Project. This includes GTK Mintec, in relation to metallurgical and processing flow sheet and pilot test work, and WSP, who’s previously announced environmental baseline mandate forms part of the broader technical work program around Skaergaard. The Company believes this combination creates an unusually strong and complementary team of advisors for the Project, bringing together expertise across geology, metallurgy, infrastructure, environmental work and development planning.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Greenland Mines Engages GTK Mintec for Comprehensive Metallurgical and Processing Flow Program at Skaergaard
PR Newswire
Establishes end-to-end processing and pilot testing program to unlock multi-metal value at Skaergaard
CHARLOTTE, N.C., April 23, 2026 /PRNewswire/ — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML) announces that it has entered into a framework agreement with GTK Mintec, the mineral processing and circular‑economy pilot plant of the Geological Survey of Finland (GTK). The agreement is to carry out an extensive mineralogical, metallurgical, processing and environmental / hydro‑geochemical investigation program for the Company’s Skaergaard Gold, Palladium, Platinum and Critical Metals Project in East Greenland.
Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Bo Møller Stensgaard, Ph.D., Greenland Mines Ltd. President, commented, “Bringing GTK Mintec into the Skaergaard story is a major step forward for our project. They are, in our view, one of the strongest mineralogical and metallurgical pilot‑testing set‑ups in Europe – combining top‑tier researchers, a unique industrial‑scale pilot plant and a dedicated tailings and process‑water research platform, all under the umbrella of the Geological Survey of Finland.
“Skaergaard is a complex, fine‑grained, multi‑metal layered intrusion. To unlock its full potential in gold, palladium, platinum and the bulk metals like iron, titanium and vanadium, we need a partner that can go deep into the mineralogy, petrology and process design, and is willing to explore both conventional and cutting‑edge low‑emission processing routes. GTK Mintec has repeatedly demonstrated exactly that approach, not only in Finland but also in a wide range of EU‑funded and international projects with commercial mining companies.
“With GTK Mintec, our technical team and SLR Consulting working together, we are putting in place a world‑class platform to design and pilot‑test a flowsheet that aims to recover as much value as possible from Skaergaard – from the precious metals through to potential Fe‑Ti‑V and other critical‑metal products – while at the same time building a strong understanding of tailings, process water and environmental performance from day one. For both institutional and retail investors, this should underline that Skaergaard is on a clear path towards becoming a technically robust, environmentally responsible and strategically relevant operation and a project that is increasingly positioned to attract strategic and financing partners as we advance toward the next set of development decisions,” concluded Dr. Stensgaard.
GTK Mintec, located in Outokumpu, Finland, combines state‑of‑the‑art mineral research laboratories with an industrial‑scale pilot plant, a dedicated tailings and extractive‑waste test area, and process‑water research facilities, providing an end‑to‑end platform from ore to tailings and reuse.
The facility has been operating since the mid‑1980s, now handling around 100 projects per year, including 8–12 industrial‑scale pilot runs, with a strong focus on critical raw materials, base metals, PGMs and battery minerals from both primary ores and secondary streams.
A leading partner for complex, fine‑grained deposits
GTK Mintec is widely recognized as one of Europe’s leading mineral processing research and pilot‑testing centers, with particular strength in fine‑grained, complex and polymetallic ore types. This includes layered mafic intrusions, titanomagnetite‑bearing iron‑titanium‑vanadium systems, and low sulphide precious metal deposits.
GTK Mintec’s Outokumpu pilot plant and laboratories have supported feasibility‑level and pilot campaigns for multiple Nordic and international mining projects, including the Hautalampi Ni‑Cu‑Co project in Finland. It has been a core technical partner in a series of EU‑funded raw materials and circular economy initiatives together with commercial mining and processing companies. Through these programs GTK Mintec has built a broad international network of industrial and research partners, which it can draw on for specialized expertise relevant to Skaergaard.
Through GTK Mintec, GTK also maintains an extensive international network of collaborators across academia, research institutes, and industry in Europe, Africa, and other regions, and participates in numerous EU Horizon and ERDF projects aimed at developing innovative pilot solutions for sustainable raw‑materials production. This combination of independent geological survey quality assurance and commercial pilot‑plant experience makes GTK Mintec a particularly strong fit for advancing a project of Skaergaard’s scale and complexity.
Scope of work – from mineralogy to pilot‑scale processing and tailings
Under the new framework agreement, GTK Mintec will work in close collaboration with Greenland Mines, the Company’s appointed Qualified Persons and other technical advisors to design and execute an integrated testwork program that spans the full value chain from ore characterization to pilot‑scale processing and tailings behavior.
Key work packages currently envisaged include:
Advanced mineralogical characterization using tools such as MLA/QEMSCAN and EPMA to define liberation, grain size, associations and deportment for gold, palladium, platinum and associated critical metals (e.g. vanadium, gallium, germanium, titanium, iron), building on more than a dozen historical bench‑scale studies
Gold deportment and hydroseparation studies on multiple feed types to refine understanding of PGM and gold occurrence in the fine‑grained Skaergaard mineralization
Beneficiation testwork, including, particle‑size and size‑by‑size chemical analysis, grinding and liberation optimization, gravity separation, magnetic separation (LIMS / HIMS) and bench‑scale flotation to test alternative flowsheets for recovering PGM‑rich concentrates and Fe‑Ti‑V‑rich magnetite/ilmenite products
Hydrometallurgical testwork, including leaching and pressure‑leach / autoclave tests on concentrates, and evaluation of modern low‑emission processes such as chloride leaching, pressure oxidation and emerging alternative routes (e.g. Kell‑type and molten‑salt‑based processes) as potential complements to conventional smelting
Pilot‑scale processing, using a large bulk sample (expected to be in the order of 10–20 tonnes from multiple locations, supported by 2026 drill core and surface channel samples) to conduct continuous pilot campaigns in GTK Mintec’s industrial‑scale pilot plant, allowing validation of the selected flowsheet under near‑industrial conditions and generation of process design data
Tailings and extractive‑waste studies, including production of representative tailings from pilot campaigns for geochemical and geotechnical characterization, evaluation of acid‑generation potential (expected to be low given the very low sulphide content), process‑water recycling behavior and long‑term tailings performance using GTK Mintec’s dedicated SMARTTEST and tailings‑test platforms
This program is intended to integrate seamlessly with Greenland Mines’ ongoing and planned work on ore sorting, pre‑concentration, Fe‑Ti‑V‑Ga‑Ge recovery options, and tailings and water‑management concepts for both open‑pit and underground development scenarios at Skaergaard.
Kimmo Tiilikainen, Director General of Geological Survey of Finland, commented, “Skaergaard is a geologically exceptional deposit, and we are excited to collaborate with Greenland Mines on this project. GTK´s role is to provide impartial research data to support the project through mineralogical characterization, development of beneficiation solutions, evaluation of recovery potential from mineral resources, and assessment of the environmental impact of mining waste. The collaboration will promote the efficient and sustainable utilization of metals and minerals from both primary ores and side streams, leveraging GTK Mintec’s strong expertise in metallic and industrial mineral ores, advanced research methods and specialized infrastructure.”
The GTK Mintec program is being planned in parallel with the Company’s upcoming field work at Skaergaard, and Greenland Mines will update the market on the integrated 2026 workplan and related milestones in due course.
A perfect match for Skaergaard’s bulk, multi‑metal potential
Skaergaard is a large, layered mafic intrusion hosting one of the world’s largest undeveloped palladium‑gold‑platinum resources, with additional potential for iron, titanium, vanadium, gallium and other critical metals in vanadium‑bearing titanomagnetite and related phases. The deposit is fine‑grained and strongly layered, requiring a sophisticated combination of petrological understanding, mineralogical detail and modern processing technology to unlock its full value.
GTK Mintec’s philosophy of maximizing recovery from both primary ores and side streams, and its focus on “extracting everything possible” from a deposit through integrated mineralogical, beneficiation and tailings work, aligns closely with Greenland Mines’ bulk‑approach to Skaergaard and its goal of designing a flowsheet that can capture value from both precious‑metal and bulk‑metal streams.
The GTK Mintec program also fits directly into Greenland Mines’ broader North Atlantic Processing Site Strategy, under which Skaergaard ore would be mined and pre‑processed in East Greenland and then shipped a short distance to Iceland for low‑carbon downstream processing. Together, the GTK Mintec testwork and the Company’s Icelandic site‑evaluation work are key technical pillars in building an integrated North Atlantic critical‑minerals corridor linking Greenlandic resources with European and North American markets.
For investors, the engagement of GTK Mintec is another clear signal that Skaergaard is moving beyond resource definition into the kind of deep metallurgical and processing work normally associated with advanced development projects. This is exactly the kind of de‑risking and value‑engineering work that can have a material impact on future project economics, payback and optionality, well beyond what drilling alone can deliver.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
GREENLAND MINES ENTERS INTO LOI TO EVALUATE BROWNFIELD DOWNSTREAM ICELANDIC INDUSTRIAL PROCESSING SITE, OUTLINES STRATEGIC SUPPLY CHAIN SECURITY PROGRAM
PR Newswire
CHARLOTTE, N.C., April 16, 2026 /PRNewswire/ — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML) has entered into a non-binding Letter of Intent with an Icelandic industrial site owner, providing a concrete framework for technical, commercial, and permitting discussions.
Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)
The Company is also in discussions with additional parties and stakeholders in Iceland and in the broader North Atlantic region about these options and support for these.
This forms the first step in the Company’s strategy as it takes advantage of its unique location, to evaluate multiple proximate industrial sites around Iceland and the North Atlantic with the purpose of identifying potential locations for a future downstream processing hub for material from the Company’s Skaergaard Gold, Palladium, Platinum and Critical Metals Project in East Greenland.
Key elements of the North Atlantic processing strategy, which could save over $1 billion in life of mine energy costs while producing green Palladium, Platinum and Gold and Critical Minerals as end products, include the following:
Evaluating multiple large industrial zoned sites in Iceland, potentially with existing industrial buildings and facilities that can be refurbished, with deep water harbor access and robust power grid connections for a future Skaergaard processing hub
Leveraging Iceland’s low-carbon geothermal and hydropower system to target a step-change in processing power costs and significantly lower the overall project carbon footprint
Refurbishing substantial brownfield industrial complexes where possible, reducing capital intensity and timelines by re-using existing buildings, heavy foundations and other infrastructure
Embedding Skaergaard within a broader North Atlantic critical-minerals corridor, linking world-class geology in Greenland with world-class energy, infrastructure and logistics in Iceland for secure supply into North American and European markets
Bo Møller Stensgaard, President of Greenland Mines, commented, “By moving now to evaluate multiple industrial sites in Iceland – and by already having a signed non‑binding Letter of Intent in place for such an activity with a local industrial site owner – we are turning our North Atlantic processing vision into a real, structured program. Replacing diesel‑based power with hydropower can translate into tens of millions of dollars in annual savings for a full‑scale plant, which is the kind of step-change that matters for a project like Skaergaard.
“Our goal is to build an integrated North Atlantic critical‑minerals corridor that investors and governments alike can get behind: world‑class geology and strong regulatory resource framework in Greenland, world‑class green and cheap energy and infrastructure in Iceland, and a clear route into North American and European value chains and industrial eco‑systems. This is how we intend to differentiate Skaergaard and to keep adding value for our shareholders as we take the project through its next development phases.”
The strategic program focuses on identifying large, industrial-zoned areas in Iceland in the range of approximately 100,000–200,000 square meters, with deep-water harbor access, potential for existing industrial buildings and heavy foundations, and power-grid connections to Iceland’s low-carbon geothermal and hydropower system.
Several of the sites under review and discussion include substantial brownfield industrial complexes that could be relatively cost-effectively refurbished and repurposed for Skaergaard’s processing requirements, potentially reducing both capital costs and construction timelines while re-using existing infrastructure in a responsible way.
A key driver behind the Iceland strategy is power cost and carbon footprint. In many remote Arctic locations, large-scale mineral processing would rely on diesel-based power generation, where all-in power costs can easily get into US$0.20 per kWh or higher. By contrast, long-term industrial users in Iceland drawing on geothermal and hydropower have historically secured materially lower effective tariffs, and the Company believes that a realistic objective for a future large industrial-scale processing operation is to reduce power costs to potentially below US$ 0.03 per kWh.
Comparable industrial use in Iceland, for example, would be for the large aluminum smelters in Iceland that are currently in operation. At a full-scale processing facility with a continuous demand on the order of, for example, 50 MW (ca. 430 GWh per year), this illustrative represents a potential transformative improvement in project economics and resilience through the cycle. The potential cumulative Life of Mine savings could exceed $1 billion relative to a diesel-based Arctic operation.
Beyond power, Iceland offers a rare combination of year-round, ice-free deep-water ports, established industrial park frameworks, an experienced industrial workforce, and proximity to both Europe and North America. Construction cost and time for a large industrial complex would also be lower in Iceland.
Skaergaard is located roughly 400 km from deep-water facilities in northwestern Iceland and around 600 km from the Reykjavík area, corresponding to an estimated bulk-carrier sailing time on the order of about 20–30 hours, which further underlines the logistical fit between mine-site operations in East Greenland and a future processing hub in Iceland.
As part of this emerging North Atlantic value chain concept, Greenland Mines is also evaluating pre-processing options in Greenland, such as crushing and ore-sorting to produce a semi-upgraded product before shipment to Iceland for downstream extraction and refining in Iceland. This is one of the scenarios being considered. Such a staged approach could reduce shipping volumes and optimize energy use between Greenland and Iceland and further enhance Skaergaard’s overall economic and environmental performance, subject to future technical studies and permitting.
For Skaergaard, that creates the possibility of an integrated North Atlantic value chain: ore mined and concentrated in East Greenland, shipped a relatively short distance to Iceland for low-carbon processing, and from there into European and North American critical-minerals supply chains.
The Company sees this as fully aligned with a growing policy focus on secure, transparent and geopolitically robust supply routes for critical and strategic metals, and with broader North Atlantic cooperation on infrastructure, security and economic development.
For investors, the combination of one of the world’s largest undeveloped palladium-gold-platinum resources with additional potential critical and bulk metals, such as vanadium, gallium, titanium and iron, in Greenland with the prospect of a low-carbon, low-cost, infrastructure-rich processing hub in Iceland represents a powerful, differentiated opportunity. It speaks directly to project economics, ESG performance, jurisdictional quality, structural investments and developments, and long-term strategic relevance.
This North Atlantic processing initiative runs in parallel with the Company’s ongoing technical, environmental and permitting work at Skaergaard, and forms a core part of its strategy to systematically de-risk the project’s development pathway ahead of future study milestones.
For governments and policy-makers, the concept offers a tangible example of cross-border industrial development in the North Atlantic, leveraging complementary strengths – geology in Greenland, energy and infrastructure in Iceland, development and security in the North Atlantic and critical metals for Western allies – in a way that supports critical-minerals resilience, industrial and compliant development within robust regulatory frameworks, climate objectives and regional stability.
As a NATO member with a dormant but potentially soon-to-be-re-activated EU accession track, and with the ability to host green geothermal-powered processing of Skaergaard metals instead of diesel-generated power, Iceland provides a uniquely strategic bridge into European and North American transatlantic markets for low-carbon, security-of-supply aligned metals under evolving climate and critical-raw-materials policies. Skaergaard thereby emerges as a potential large-scale, industrial- and policy-aligned opportunity for climate-friendly “green” gold, palladium, platinum, vanadium, gallium, iron, steel and titanium.
Importantly, any potential development of activities in Iceland and Greenland will be subject to well-established environmental and social regulatory frameworks and approval, including complete permitting, environmental and social impact assessments and structured community consultation. Greenland Mines is fully committed to environmental compliance – not only to safeguard nature and the environment, but also to position Skaergaard as an attractive platform for potential strategic and financing partnerships as the project advances and as a reliable, attractive and long-term partner to downstream industrial users of precious, critical and bulk metals.
The Company expects the findings from this Iceland site‑evaluation program to feed into future technical studies for Skaergaard and will update the market as material milestones are reached.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Greenland Mines Subsidiary Major Precious Greenland A/S Joins Greenland Business Association
PR Newswire
Enhances stakeholder engagement and supports long-term project development in Greenland
CHARLOTTE, N.C., April 2, 2026 /PRNewswire/ — Greenland Mines Ltd (Nasdaq: GRML) (“Greenland Mines” or the “Company”), through its 80%-owned Greenlandic subsidiary Major Precious Greenland A/S (“MPG”), announces that MPG has become a member of Greenland Business Association (Sulisitsisut), the leading organization representing businesses across Greenland.
Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)
“Our subsidiary Major Precious Greenland A/S joining Greenland Business Association is another concrete step in building a strong, long‑term presence in Greenland. We are not just bringing high‑quality projects; we want to be an active part of the Greenlandic business community and contribute to sustainable economic development as an active and trusted partner,” said Greenland Mines President Bo Moller Stensgaard. “Through Greenland Business Association, we gain a valuable forum for dialogue with Greenlandic companies, organizations, and decision‑makers. This will help us shape projects that create lasting value for Greenland, while meeting the expectations of local communities, employees, partners, and our global investor base.”
Greenland Business Association is an independent employers’ and business organization working to promote competitive and sustainable economic development and a strong framework for private enterprises operating in Greenland. By joining the Association, Greenland Mines and its subsidiary strengthen their local profile and embeds themselves deeply in the national dialogue on responsible resource development, employment, and long‑term value creation in Greenland.
Strengthening local presence and dialogue
Membership of Greenland Business Association provides Greenland Mines, through its subsidiary, with a structured platform to engage with Greenlandic companies, politicians, and community partners across a wide range of sectors. These include mining, energy, logistics, construction, services and tourism. Through this network, the Company aims to:
Contribute actively to discussions on responsible mineral resource development and long‑term economic opportunities in Greenland
Build and deepen relationships with Greenlandic suppliers, contractors, and service providers
Support knowledge sharing on best practices in areas such as health and safety, environment, labor standards, and community relations
For Greenland Mines, this step complements its technical and environmental work, underlining the Company’s commitment to building its Skaergaard Au-Pd-Pt and critical metal project in close cooperation with Greenlandic stakeholders and institutions.
Supporting long‑term value creation in Greenland
Greenland Business Association works to improve the general business environment in Greenland, including issues such as infrastructure, education and skills, taxation and regulation, and access to labor and capital. As part of the Association, the Company will have the opportunity to participate in working groups and policy discussions that are directly relevant to the development of large‑scale, long‑life industrial projects such as a potential advanced mineral operation at the Skaergaard Au-Pd-Pt and critical metal project in East Greenland.
The Company believes that early and proactive involvement in Greenland’s business community will help ensure that future activity around projects such as Skaergaard can maximize local participation, employment, and supply‑chain development, while maintaining high standards for environmental and social performance.
Christian Keldsen, Director, Greenland Business Association, added, “We are pleased to welcome Major Precious Greenland A/S and its parent company Greenland Mines Ltd into Greenland Business Association. Mining, when developed responsibly, can play an important role in diversifying Greenland’s economy, creating jobs and building new business opportunities for Greenlandic companies.
“Seeing a NASDAQ‑listed company invest in Greenland and commit to working within our business community is a positive signal to both local and international stakeholders. Greenland is open for business and investments. We look forward to a constructive collaboration with Greenland Mines as they progress their Skaergaard Au-Pd-Pt and critical metal project and as we jointly work to attract sustainable investment and development to Greenland,” concluded Mr. Keldsen.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Greenland Mines Secures Icebreaker Argus For 2026 Skaergaard Field Program
PR Newswire
Ice-class vessel deployment strengthens Arctic logistics infrastructure and enables efficient execution of the 2026 Skaergaard field program
CHARLOTTE, N.C., March 25, 2026 /PRNewswire/ — Greenland Mines Ltd. (“Greenland Mines” or the “Company”) (Nasdaq: GRML) announces entry into a charter agreement with IceTugs ApS (“IceTugs”) for the deployment of the icebreaker support vessel M/V Argus during the Company’s 2026 field season at the Skaergaard Gold-Palladium-Platinum and Critical Metal Project in eastern Greenland.
Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Under the agreement, M/V Argus will transport supplies, equipment, drill rigs, fuel, and personnel from Reykjavík, Iceland, to the Skaergaard area and adjacent fjords. It will also serve as the primary offshore logistics hub while anchored in the inner part of the deep-water sheltered fjord Mikis Fjord adjacent to the shores at Skaergaard Project and the airstrip at Sødalen for the duration of the field campaign.
The vessel will provide accommodation, marine logistics, and operational support for Greenland Mines’ geological and technical programs at Skaergaard.
Greenland Mines President, Bo Møller Stensgaard, said, “Chartering M/V Argus for the 2026 field season is a major operational win for Greenland Mines. There are only a handful of vessels like this available in the North Atlantic and having a true Iceclass A1 Super icebreaker with a helideck, large accommodation capacity, and a seasoned Arctic crew dedicated to Skaergaard gives us a tremendous advantage in terms of safety, flexibility and efficiency.
“Together with our newly announced environmental baseline program, securing M/V Argus underlines how we are positioning Skaergaard on a fast, but disciplined, development track. We are encouraged at our rapid progress, putting world‑class assets and partners in place – both on the environmental side and on the operational side – as we work to unlock the full potential of this unique precious metals project in eastern Greenland.”
A rare, top‑tier Arctic asset
M/V Argus is a powerful, steel offshore support and rescue vessel with Iceclass A1 Super and Polar Code compliance. It is designed specifically as an expedition vessel and for operating safely in demanding North Atlantic and Arctic conditions, including narrow deep-water fjords along the Greenland coastline. The ship is highly maneuverable, robust and reliable, and has been modified to make the field crew for the season staying on board comfortable, with mess, office and working areas.
The vessel offers accommodation for up to approximately 40–50 persons, providing ample capacity for multi‑disciplinary field teams, logistics, contractors, and aviation personnel. M/V Argus is equipped with a certified helicopter deck and designated special aviation fuel storage, which allows integration of helicopter operations directly from the ship – a key enabler for efficient access to the Skaergaard site and surrounding region.
In addition to M/V Argus, IceTugs operates a flexible fleet of tugboats and cargo vessels tailored to Arctic logistics, providing Greenland Mines with further options to support phases of work in Greenland.
Securing M/V Argus for the 2026 season is a significant milestone, as there are very few vessels of comparable ice‑class, capacity, and Arctic track record available in the North Atlantic, and demand from expedition, science and commercial users is high.
Proven experience on Greenland’s east coast
IceTugs and M/V Argus have extensive experience along the Greenland coast, including repeated voyages into East Greenland fjords for expeditions and science campaigns, as well as operations in challenging ice conditions. The captain and crew are accustomed to Arctic navigation, safety and emergency procedures, and operate in accordance with international standards for polar operations and Bureau Veritas classification requirements.
For the Skaergaard 2026 program, M/V Argus will anchor in the project, providing a stable platform for daily helicopter operations, support for drill rigs, smaller boat operations, cargo handling, and safe accommodation throughout the season. The vessel’s cargo holds, deck space, and fuel/water capacity are well suited to support extended field operations and to carry additional diesel for drill rigs and onshore technical equipment and spare parts.
Enabling an efficient 2026 Skaergaard campaign
The combination of M/V Argus’ icebreaking capabilities, helideck, accommodation, and cargo capacity allows Greenland Mines to execute an integrated efficient technical field program in 2026, tightly coordinated with the Company’s environmental baseline work and advanced studies at Skaergaard. Operating from a single, well‑equipped Arctic vessel reduces logistical complexity, enhances safety, and maximizes productive field time for geology, environmental surveys, and technical teams.
By locking in M/V Argus early, Greenland Mines believes it has secured one of the most capable and sought‑after Arctic support vessels in the region, reinforcing the Company’s commitment to safe, efficient and professional field execution as it advances Skaergaard toward an exploitation license application.
The nearby gravel airstrip at Sødalen next to Skaergaard will be used to lift in short-term topic specialists on specific technical tasks and evaluations that all will feed into the next development phase for the Project.
About Skaergaard – a Unique Precious and Strategic Metals Opportunity
The Skaergaard intrusion is recognized as one of the world’s largest undeveloped resources of gold‑palladium‑platinum, with additional metals that are increasingly important to energy transition, defense application and high‑technology supply chains.
While the project area has benefitted from decades of geological, resource and academic work, historical environmental datasets are relatively limited, making the current, large‑scale baseline program a critical enabler for responsible, long‑life mine development.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance
PR Newswire
Extension reflects Company’s continued compliance with all other applicable Nasdaq listing requirements
CHARLOTTE, N.C., March 23, 2026 /PRNewswire/ — Greenland Mines Ltd (Nasdaq: GRML) (“Greenland Mines” or the “Company”) today announced that it has received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an additional 180-day period, through September 14, 2026, to regain compliance with Nasdaq’s minimum bid price requirement.
Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)
The extension reflects Nasdaq’s determination that the Company meets all other applicable listing requirements, including those related to market value of publicly held shares and other continued listing standards.
As previously disclosed, the Company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period to regain compliance with Nasdaq’s requirements.
Greenland Mines remains committed to maintaining its Nasdaq listing and advancing the development of its strategic mineral resources and cell and gene therapy assets.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Greenland Mines Engages WSP Denmark to Launch Comprehensive Environmental Baseline Program at Skaergaard Mining Site
PR Newswire
Engagement supports exploitation license pathway while advancing responsible, large-scale development of the Skaergaard Project
CHARLOTTE, N.C., March 19, 2026 /PRNewswire/ — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML) is pleased to announce that it has entered into a consultancy agreement with WSP Danmark A/S (“WSP Denmark”), part of the global WSP group, to design and implement a full Environmental Impact Assessment (“EIA”) baseline program at the Company’s Skaergaard Gold-Palladium-Platinum and Critical Metal Project in eastern Greenland.
Under the terms of the agreement, WSP Denmark will provide technical advice and assistance related to baseline surveys for the EIA, support the development of the Terms of Reference (“ToR”), and prepare the EIA report required for an exploitation license application to the Government of Greenland (Naalakkersuisut). This is structured to align with Government of Greenland’s updated exploitation permitting framework from 2025.
“Formalizing our collaboration with WSP Denmark is the key component to launching this comprehensive environmental baseline program at Skaergaard well ahead of statutory requirements. This is a clear statement of our intent: we are building Skaergaard for the long term, and we will only do so in a way that meets the highest environmental standards and expectations in Greenland,” said Greenland Mines President Bo Moller Stensgaard. “WSP’s deep Arctic experience, their strong track record on mining EIAs in Greenland, and their access to global mining and processing expertise provides the exact technical foundation to complete this stage of the project. Coupled with Skaergaard’s scale and strategic metals profile, this work marks an important step on our fast, but responsible, development trajectory.”
Strong Platform for Exploitation License
Greenland Mines Logo
The work program with WSP Denmark is designed to meet the environmental requirements associated with the Company’s planned exploitation license application, including Terms of Reference (“ToR”) preparation, environmental baseline data collection, and the drafting of a compliant EIA for public consultation and regulatory approval.
By initiating the environmental work, Greenland Mines is both accelerating the Skaergaard development and permitting process and demonstrating a strong, long‑term commitment to responsible development in Greenland.
Two‑Year Arctic Environmental Baseline Program
As part of the EIA, which must be submitted after the granting of an Exploitation License, Greenlandic authorities typically require at least two years of prior biological baseline surveys covering the full project area and realistic development alternatives. The work program in 2026 and 2027 intend to cover this requirement.
WSP Denmark’s scope for Skaergaard includes:
Installation of automated weather stations (near the Sødalen airstrip and the potential site for infrastructure, harbor and processing facilities at site) to continuously record temperature, wind, precipitation and humidity, with satellite data transmission
Establishment of hydrological monitoring stations on key rivers to measure water levels and flows, supporting assessments of water use for processing and tailings management
Extensive terrestrial and marine baseline work, including vegetation and habitat mapping, systematic observations of mammals and birds, and dedicated sea mammals monitoring via several marine submerged hydrophone stations
Collection of biological and environmental samples for archiving in the Greenland Mineral Resources Environmental Sample Bank, following updated Greenlandic sampling guidelines
Detailed marine seabed characterization using submerged underwater Remote Operated Vehicle video and grab sampling in areas relevant to potential sites for harbor and other facilities
A comprehensive baseline report will be delivered after the 2026 campaign, with a final baseline report, and in parallel approvement of ToR and first draft EIA targeted after completion of the 2027 program.
About WSP Denmark – Arctic and Mining Expertise with Global Reach
WSP Denmark brings extensive Arctic environmental and permitting experience, including multiple mining and infrastructure projects in Greenland and the broader North Atlantic region, and operates within WSP’s global platform of mining, processing and environmental specialists. This combination allows Greenland Mines to access both local Greenlandic and international best practice in areas such as mine design, water management, tailings, biodiversity, climate resilience and closure planning.
About Skaergaard – a Unique Precious and Strategic Metals Opportunity
The Skaergaard intrusion is recognized as one of the world’s largest undeveloped resources of gold‑palladium‑platinum, with additional metals that are increasingly important to energy transition, defense application and high‑technology supply chains.
While the project area has benefitted from decades of geological, resource and academic work, historical environmental datasets are relatively limited, making the current, large‑scale baseline program a critical enabler for responsible, long‑life mine development.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
PR Newswire
Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland
CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO) (“Klotho” or the “Company”) today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to “GRML” effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
The Company will hold an investor webcast on Thursday, March 12, 2026 at 4:15PM ET to discuss the strategic rationale of its recent acquisition and benefits for shareholders.
Investor Update Participation Details:
Date: Thursday March 12, 2026
Time: 4:15 PM ET
Participant Dial-In: USA/Canada (toll-free) 1-877-270-2148; International 1-412-902-6510. Participants should request to join the Klotho Neurosciences call.
Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=q7dUp2aG
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
contact@greenlandmines.com
Website: www.greenlandmines.com
KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR
PR Newswire
Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland Mines
CHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO) (“Klotho” or the “Company”) today announces the acquisition of Greenland Mines Corp. (“Greenland Mines” or “GMC”), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum deposits in the world. The Company entered into a definitive merger agreement with Greenland Mines on March 3, 2026, and is closing the acquisition on March 4, 2026. Post-closing, Klotho’s CEO and CFO will remain in place. The Greenland Mines leadership team, led by CEO Bo Møller Stensgaard, will join the management team to operate the Greenland Mining division, and one new Board member will be added. The Company will now operate under two strategic operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
“Today marks a defining chapter for Klotho Neurosciences and our shareholders. The Skaergaard Project is truly extraordinary — an approximately $68 billion in-situ resource in palladium, gold, and platinum, sitting in one of the most geopolitically secure jurisdictions on earth, less than 1,600 kilometers from the U.S. This is the kind of asset that reshapes a company’s trajectory overnight, and our shareholders now have direct ownership in it,” stated Klotho Neurosciences CEO Dr. Joseph Sinkule. “We are pairing this world-class mineral asset with our existing biotech platform, creating a uniquely diversified company that gives investors exposure to both cutting-edge life sciences and strategic natural resources. We believe this to be an important opportunity to significantly contribute to the mission of securing Western access to critical minerals.”
Full consideration for the transaction is payable in convertible preferred stock, the conversion of which is subject to shareholder approval. On an as-converted basis, Greenland Mines Corp. is expected to own approximately 93% of fully diluted shares outstanding. The transaction is expected to be treated as a reverse merger for accounting purposes. The Company intends to change its name and stock ticker in late March 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol.
A PIVOTAL MOMENT FOR SHAREHOLDERS: ACCESS TO A WORLD-CLASS ASSET
The Skaergaard Intrusion is not merely a mining project — it is a geological phenomenon. Discovered in 1935 and studied by Cambridge, Caltech, and the Geological Survey of Denmark and Greenland, Skaergaard is one of the most significant layered mafic intrusions ever documented. In 1986, a giant strata-bound gold and palladium deposit of a previously unknown type — the “Triple Group” — was confirmed across seven mineralized horizons.
The 2022 NI 43-101 Technical Report (SLR Consulting; ~45,000 meters of diamond drilling) established a Total Indicated and Inferred Resource of 364.37 million tons at 2.17 g/t PdEq, with the Indicated category alone at 158.95 million tons grading 2.22 g/t PdEq. This constitutes 25.4 million ounces of palladium equivalent (“Moz PdEq”) and 23.5 million ounces of gold equivalent (“Moz AuEq”) in combined Indicated and Inferred Resource categories at the effective date of the NI 43-101 Technical Report. The deposit is open in all directions, with mineralization confirmed beneath the Forbindelses Glacier and on the Northern Plateau.
The Skaergaard Project carries a gross undiscounted in-situ resource value of approximately $68 billion — $30.8 billion in palladium, $34.8 billion in gold, and $3 billion in platinum (based on gold at $5,100/oz, palladium at $1,800/oz, and platinum at $2,175/oz)1. Over $100 million in historical investment would be required to replicate the exploration work completed to date. The asset ranks among the top undeveloped palladium-gold deposits on earth by gold equivalent value, ahead of Wafi-Golpu (Papa New Guinea), Golden Summit (Alaska), and Snowfield (BC, Canada).
The Company is fully permitted for exploration with environmental and metallurgical studies underway. Site access is established via a licensed airstrip at Sødalen, helicopter logistics, and seasonal sea access via Mikis Fjord. Three Mineral Exploration Licences total 877 km² of prospective ground.
The Company believes the current resource estimate does not represent the true scope of Skaergaard. The deposit remains open in all directions. Drilling campaigns have continuously returned consistent positive grades and widths, and the 2022 NI 43-101 update delivered a 95% increase in Indicated resources and a 28% increase in total contained metal over the prior estimate. The ultimate size of this deposit is expected to materially exceed current estimates.
“This acquisition marks a transformational moment — not just for our shareholders, but for American and European strategic resource security. The Skaergaard Intrusion is one of the most significant undeveloped palladium and gold deposits on the planet, located in Greenland, one of the safest and most accessible jurisdictions in the world,” stated Greenland Mines Corp. CEO Bo Møller Stensgaard. “At a time when the U.S. and Europe are acutely aware of their dependence on Russia and South Africa for critical platinum group metals essential for vehicle emission systems, refining operations, clean energy technologies, and defense applications — Greenland Mines Corp. offers a credible, large-scale, and fully permitted Western alternative.
“Combined with its world-class gold resource and the potential for substantial additional critical metal by-product streams from minerals such as gallium and vanadium, the Project represents a robust, highly attractive, and diversified value proposition. In a tightening global supply environment, strengthening transatlantic access to critical minerals is not optional — it is a strategic imperative. We are just getting started in demonstrating the full scale and value of this asset, and we are deeply proud of what we will build for our shareholders, for Greenland, and for the future of Western critical mineral supply,” concluded Mr. Stensgaard.
PALLADIUM AND OTHER METALS’ IMPACT ON AUTO AND OTHER MANUFACTURING AND THE POTENTIAL MARKET FOR NEW SOURCES IN A COMPETITIVE ENVIRONMENT
Palladium is the backbone of automotive emissions control — 84% of global demand feeds catalytic converters in gasoline and hybrid vehicles. The U.S. auto sector, producing approximately 10 million vehicles annually and supporting over 9 million jobs, depends almost entirely on this single metal for Clean Air Act compliance. It is also critical for defense, aerospace, and electronics.
The vulnerability is severe and structural: 75–80% of global palladium originates from Russia and South Africa. Russia (via Nornickel) alone accounts for 40–45% of primary production. This concentration exposes American automakers, manufacturers, electronics companies, and healthcare device makers to extraordinary supply chain risk from sanctions, export restrictions, and political instability.
Platinum faces parallel risk — approximately 70% of global supply comes from South Africa, with Russia adding 10–15%. It is essential for catalytic converters, petroleum refining, medical instrumentation, and increasingly for hydrogen fuel cells and electrolysers central to the U.S. clean energy transition. Platinum Group Metals are classified as critical and/or strategic by the U.S., EU, Canada, UK, and NATO.
Skaergaard’s Total Indicated and Inferred Resource of 17.15 million ounces (“Moz”) palladium and 6.83 Moz gold — before planned expansion — equals 13–15 years of total U.S. palladium consumption. Gold provides universal liquidity, monetary hedging, and bankable collateral that materially strengthens the Skaergaard Project’s overall economics. Additional critical metals including gallium, germanium, and vanadium further diversify the project’s strategic value proposition
Gallium is classified as a critical mineral by both the U.S. and the EU. It is essential for compound semiconductors such as gallium arsenide (GaAs) and gallium nitride (GaN), which underpin high-frequency electronics, 5G infrastructure, radar systems, electric vehicles, and advanced defense applications. Global primary production is heavily concentrated in China, creating acute strategic vulnerability for Western economies.
Vanadium is similarly designated as critical due to its role in high-strength steel alloys for construction, infrastructure, pipelines, and defense, and its growing importance in vanadium redox flow batteries for grid-scale energy storage. Global production is dominated by China, Russia, and South Africa. Securing diversified Western supply of both gallium and vanadium is essential for semiconductor sovereignty, infrastructure resilience, defense capability, and the clean energy transition.
These additional commodity streams from Skaergaard add material value to the Project, create opportunities for integration with broader industrial supply chains, and enhance the asset’s robustness against single-commodity price fluctuations.
ABOUT KLOTHO NEUROSCIENCES, INC.
Klotho Neurosciences, Inc. is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho’s KLTO-202 primary indication for ALS. The Company holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.
Investor Contact and Corporate Communications:
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
PR Newswire
The Company enlists industry veteran Dr. Bret Barnes to oversee the development of new diagnostic offerings
NEW YORK, Feb. 24, 2026 /PRNewswire/ — Klotho Neurosciences, Inc. (“Klotho” or the Company) announces the development of two genomics-based diagnostic tests that will be utilized in Klotho’s clinical trials and to be provided as a service in the field of longevity and the understanding of the relationships between biological age and chronologic age.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
One genomics test being developed is a quantitative DNA methylation assay that determines the extent of DNA methylation of the anti-aging gene called alpha-Klotho using cell-free DNA isolated through a blood draw as a validated marker of biologic aging. The second, which the company has named the “Klotho Clock,” measures DNA sequences and the mRNA sequences of Klotho and 8 other genes described in the scientific literature as being associated with longevity and healthy lifespan. Since Klotho induces the expression of several of these genes, Klotho is of primary interest. Complementary with the genetic sequence analysis, the mRNA analysis will provide proof that the proteins are being transcribed and produced by the gene sequences.
Dr. Joseph Sinkule, Klotho Neurosciences Founder and CEO stated, “This is a unique opportunity to qualify patients with neurodegenerative diseases for our clinical trials to assure that our randomized studies are balanced and stratified based on biologic age and the extent of DNA methylation of the human Klotho gene and promoter. Similar to many other human genes, the hypermethylation of the Klotho gene and its promoter are key events that occur over time that ultimately silence the gene and lower the Klotho protein levels in all tissues. Balancing the biological age of people going into our randomized studies will minimize the possibility of overloading the placebo group with healthier, ‘less biologically aged’ people in the placebo arm versus the treatment arm of our studies.”
The Company has enlisted Dr. Bret Barnes to manage the Company’s evolving diagnostic program. Previously he worked at Illumina for 18 years, leading a small team of scientists developing DNA methylation and other bead-based genomics assays in addition to NGS structural variant informatics. Illumina, Inc. is a leading American biotechnology company headquartered in San Diego, specializing in the development, manufacturing, and marketing of integrated systems for large-scale analysis of genetic variation and function.
Dr. Barnes stated, “Unlike other genomic tests on market, Klotho Neurosciences’ assay employs novel, cutting-edge probe designs to address underlying human genetic variation, while simultaneously providing increased accuracy at a lower assay cost. The increased information from these novel designs can seamlessly integrate into our AI-based clocks. Besides DNA methylation detection, the software supporting our assay can provide information on Copy Number Variants (‘CNVs’) and Single Nucleotide Variants (‘SNVs’), thus creating new, more robust ‘multiomics’ capabilities.”
Following the development of the prototype version of the assay, expected in 2026, the Company expects a more efficient and more cost-effective diagnostic product that will serve to provide the company an immediate revenue source and begin to build a database for ‘clock’ improvements and novel ‘clock’ discoveries.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a gene and cell therapy company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from the “anti-aging” human Klotho gene (s-KL), tissue-specific promoters, and novel tissue and organ delivery systems to transform and improve the treatment of neurodegenerative disorders such as ALS, Alzheimer’s disease, Parkinson’s disease and age-related neuronal, ocular, skeletal and muscular pathologies. The “Klotho Clock” will facilitate and integrate our understanding of chronologic age versus biologic age, the relationship between human disease and healthy lifespan, and key factors that may result in extended longevity.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence
PR Newswire
NEW YORK, Feb. 18, 2026 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO) (“Klotho” or the Company) announces the acceptance of 18 claims within a patent application filed in Australia for composition and use of human secreted Klotho protein (“s-KL”) isoform of the human gene sequence. The Australian government entity IP Australia has notified the Company and the licensor of the technology, Universitat Autonoma de Barcelona, that these claims are to be granted. The 18 claims cover the use of a human muscle-cell specific promoter operatively linked to a nucleic acid gene sequence encoding human the human s-KL protein for treating motor impairment. The claims also cover the use of neuronal cells and induced pluripotent stem cells (iPSC) containing the muscle-cell specific promoter and s-KL nucleic acid gene sequence encoding human the human s-KL protein and other cellular delivery systems such as adeno-associated viral vectors or “AAV”) or non-viral vectors with muscle-cell and/or motor neuron-cell tropism.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Dr. Joseph Sinkule, founder and CEO of KLTO stated, “These claims are an important expansion of our patent estate, which we believe will help to provide momentum and security to pursue the therapeutic replacement or supplementation of human Klotho levels. As people age, they naturally lose innate, in vivo therapeutic concentrations of Klotho due to the commonly occuring DNA methylation of the promoter and gene leading to the ‘silencing’ of the Klotho gene in neuromuscular (‘motor neuron’) cells and tissues in our body. The ‘method of use’ component of these claims includes treatment, wherein the subject has a disease or disorder characterized by motor impairment, such as a neuromuscular or motor neuron disease. We believe our approach to utilizing s-KL protein is a significant innovation and we look forward to continuing to develop our capabilities around addressing Klotho supplementation, and to providing updates as they emerge.”
Neuromuscular diseases include amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease, multiple sclerosis, muscular dystrophy (both Duchenne and Becker muscular dystrophy), myasthenia gravis, myopathy, myositis, peripheral neuropathy, neuromyotonia, Lambert-Eaton disease, Friedreich’s ataxia, traumatic nerve injury, diabetic neuropathy, motor skills disorder, spinal muscular atrophy (SMA), spinal cord injury, peripheral nerve injury, traumatic nerve injury, hereditary myopathy, toxic neuropathy, autoimmune peripheral polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropahty (CIDP), drug-induced myopathy, sarcopenia, cachexia, age-related muscular atrophy, type II muscle fiber atrophy, or an acquired autoimmune primary muscle disorder. Specific motor neuron disorders or ‘MND’ include ALS, progressive bulbar palsy (PBP), pseudobulbar palsy, progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), SMA, or monomelic amyotrophy (MMA).
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a gene and cell therapy company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from the “anti-aging” human Klotho gene (s-KL), tissue-specific promoters, and novel tissue and organ delivery systems to transform and improve the treatment of neurodegenerative disorders such as ALS, Alzheimer’s disease, Parkinson’s disease and age-related neuronal, ocular, skeletal and muscular pathologies.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences to Present at the Biotech Showcase 2026
PR Newswire
NEW YORK, Jan. 8, 2026 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO, “Klotho”, or “the Company”), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting at the 2026 Biotech Showcase in San Francisco on January 13, 2026 at 11:30AM PT. The Biotech Showcase is to be held January 12-14, 2026 at the Hilton San Francisco Union Square.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
At the event, the Company will be available for one-on-one meetings with investors and potential partners. To request a meeting, please contact ir@klothoneurosciences.com.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
.
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
PR Newswire
NEW YORK, Nov. 7, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (NASDAQ: KLTO ) (the “Company” or “Klotho”), a U.S.-based biogenetics company, announces it has been selected as winner of the Fifth Annual BioTech Breakthrough Award in the “Cell Therapy Innovation of the Year” category.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer’s disease, and Parkinson’s disease. By targeting the underlying mechanisms of neuronal aging, Klotho’s therapies aim to slow, halt, or reverse disease progression, offering durable, disease-modifying benefits for patients with conditions that currently have limited treatment options.
“This award highlights our commitment to translating cutting-edge scientific discoveries into meaningful therapies for patients suffering from neurodegenerative and age-related diseases,” said Dr. Joseph Sinkule, Klotho Neurosciences’ CEO. “As the global population ages, the need for therapies that address the root causes of age-related conditions has never been greater. Klotho’s focus on the human Klotho protein positions us to meet this challenge, developing therapies that not only target neurodegeneration but also have the potential to improve health span and reduce the burden of age-related disease worldwide.”
The BioTech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the global life sciences and biotechnology industries. Conducted annually by BioTech Breakthrough, a leading independent market intelligence organization, the awards celebrate excellence across biopharma, therapeutics, genomics, diagnostics, and research tools.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
PR Newswire
NEW YORK, Oct. 16, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO, “Klotho”, or “the Company”) a U.S.-based biogenetics company, announces that members of its leadership team will attend Longevity Biotech 2025 in Boston, Massachusetts, on October 22–23, 2025. The conference convenes leaders across biotech, pharma, academia, and venture to advance the development of longevity therapeutics and will be hosted at Wightman Mansion (43 Hawes Street, Brookline/Fenway campus).
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
At the event, the Company will be available for one-on-one meetings with investors and potential partners. To request a meeting, please contact ir@klothoneurosciences.com.
Chief Executive Officer of Klotho Neurosciences Dr. Joseph Sinkule commented, “We look forward to productive discussions in Boston with peers and potential partners as the field continues to translate aging biology into therapeutic programs. Our focus remains on disciplined execution and building collaborations that can accelerate our mission.”
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences Announces Expiration of Letter of Intent
PR Newswire
NEW YORK , Oct. 7, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO, “Klotho”, or “the Company”) today announced that its Letter of Intent with Turn Biotechnologies was allowed to expire by the parties.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Following careful evaluation, Klotho’s Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and shareholders.
The longevity medicine market continues to be one of the fastest-growing global sectors, and Klotho’s current pipeline is centered around the human Klotho protein, which is considered a key component in longevity. The world’s aging population is expected to hit 2.1 billion by 2050, driving healthcare costs already at 10% of global GDP and projected to exceed $47 trillion by 2030.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
PR Newswire
NEW YORK and PALO ALTO, Calif. , Sept. 30, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (Nasdaq: KLTO, “Klotho” or “the Company”) today announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. (“Turn”), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement, and customary closing conditions. If completed, the transaction would position Klotho as a leader in the development of longevity therapeutics.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Under the LOI, Klotho would acquire Turn’s ERA (“Epigenetic Reprogramming of Age”) platform and eTurna RNA delivery system. These proprietary technologies are designed to rejuvenate somatic cells and restore tissue function, creating opportunities for a long list of regenerative therapies in dermatology, ophthalmology, immunology, osteoarthritis, muscle health and diseases like amyotrophic lateral sclerosis (“ALS”).
Importantly, as part of this transaction, Klotho will be acquiring a signed out-licensing and co-development partnership with one of South Korea’s leading pharmaceutical companies worth up to $300 million . This global partnership underscores the commercial interest in Turn’s platform and highlights the broad potential applications of its technology.
“This LOI marks a transformative step for Klotho,” said Dr. Joseph Sinkule , CEO of Klotho Neurosciences. “The Klotho gene is often referred to as the ‘anti-aging gene,’ first identified for its ability to extend lifespan in animal models and protect against neurodegenerative diseases. Our company was founded on translating that science into therapies that combat age-related decline. By adding Turn’s ERA technology — which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age — together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation. Coupled with Turn’s pharma partnership, this combination demonstrates both the scientific foundation and the commercial interest that position Klotho to pioneer therapies extending healthspan and addressing diseases of aging — from Alzheimer’s and Parkinson’s to skin, muscle, bone, and vision loss.”
Upon completion of the contemplated transaction, Klotho plans to rebrand to reflect its broadened mission and expanded therapeutic reach. Klotho also intends to bring over key members of Turn’s management and R&D teams post-close.
The longevity medicine market is one of the fastest-growing global sectors. The world’s aging population is expected to hit 2.1 billion by 2050, driving healthcare costs already at 10% of global GDP and projected to exceed $47 trillion by 2030. Klotho aims to lead this transformation by addressing aging at its root cause — the cell.
About Turn Bio
Turn Biotechnologies is a pre-clinical-stage company developing therapies to repair and rejuvenate tissue at the cellular level. Its proprietary RNA-based platform — ERA was developed at Stanford University and is exclusively licensed from Stanford and utilizes Turn’s novel eTurna delivery system. The company has raised over $30 million from leading investors, including Khosla Ventures, Astellas Ventures, Methuselah Foundation, Shanda Group, and Formic Ventures, to advance its pioneering science and expand its therapeutic pipeline. Learn more at www.turn.bio .
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
PR Newswire
NEW YORK , Sept. 8, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (NASDAQ: KLTO) (“Klotho” or “the Company”), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, announces CEO and Chairman Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar. The event, the first ever conference on the future of klotho-based therapies and diagnostics, will be held at the UC-Irvine Beal Applied Innovation Center in Irvine, Calif. September 15-16, 2025 .
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
The Company’s two key scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch will be presenting their research achievements exploring Klotho gene therapy in the treatment of ALS, Alzheimer’s and longevity.
Dr. Sinkule will be available to meet with investors and potential partners during the conference. Interested parties can contact ir@klothoneuro.com .
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. KLOTHO is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
PR Newswire
Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics
NEW YORK , Aug. 18, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (NASDAQ: KLTO) (“Klotho” or “the Company”), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company’s key milestones and pipeline progress. These achievements strengthen Klotho’s position as it advances toward the large and growing market for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease therapies, which is estimated at over $8 billion annually by Grand View Research and others.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Over the course of this year, Klotho Neurosciences has achieved critical strategic and operational milestones:
Pipeline Advancement and Regulatory Recognition: The company received Orphan Drug Designation from the FDA for KLTO-202 for the treatment of ALS, reinforcing the therapeutic potential of its Klotho-based programs to address significant unmet medical needs
Strategic Partnerships: Klotho entered a binding agreement with AAVnerGene, Inc. to manufacture and develop its KLTO-202 gene therapy candidate using AAVnerGene’s platform, accelerating preclinical studies and optimizing delivery of its therapeutic candidates. The Company has since initiated manufacturing of KLTO-202
R&D Expansion and Capabilities: The company launched a research center in Okinawa , Japan , and expanded its internal development team , strengthening preclinical research, biomarker development, and operational expertise
Financial and Market Positioning: Klotho successfully raised over $11 million in financing to advance its programs, eliminating all debt and regaining full compliance with Nasdaq listing requirements , ensuring continued trading and investor confidence
Independent Control of Pipeline: Following the mutual termination of its collaboration with SkyBell, Klotho retains full global rights to its Klotho programs, positioning the company to pursue development and commercialization on its own terms
Klotho CEO Dr. Joseph Sinkule commented, “2025 has been a transformative year for the Company. We are executing a focused and disciplined strategy to advance our Klotho-based therapeutics from preclinical development toward clinical evaluation, while simultaneously strengthening the Company’s operational and scientific foundations and carefully managing our resources. Through strategic partnerships, expanded research capabilities, and the addition of key talent, we have enhanced our ability to drive program development efficiently and effectively. These accomplishments, together with regulatory progress and financial positioning, reinforce our capacity to maximize the potential of our pipeline, expand our technological footprint, and deliver sustained value creation for our shareholders as we continue to advance innovative solutions in neurodegenerative and age-related diseases.”
Building on its 2025 progress, the Company is positioned to pursue the following key objectives:
Accelerate preclinical and IND-enabling studies for KLTO-202.
Evaluate complementary technologies and acquisitions to enhance pipeline breadth in brain health, organ function, and longevity.
Continue expanding internal capabilities to strengthen R&D, manufacturing, and clinical readiness.
With these strategic initiatives, Klotho Neurosciences is building on its 2025 successes to advance its leadership in Klotho-based therapeutics and create meaningful long-term value for shareholders.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. KLOTHO is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
PR Newswire
NEW YORK , Aug. 12, 2025 /PRNewswire/ — Klotho Neurosciences, Inc . (Nasdaq: KLTO ), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc . (AAVnerGene) platform technology. As previously announced , AAVnerGene is an innovation-driven biotech renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery. KLOTHO is a biotechnology company focused on the development of groundbreaking, disease-modifying cell and gene therapies using a human gene and protein derived from its patented form of the “anti-aging” Klotho gene.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
Dr. Joseph Sinkule , KLOTHO CEO, stated, “The AAVnerGene technology is a game-changer in manufacturing AAV vectors for intracellular delivery of genes. The initiation of manufacturing is a key milestone in the development of any biotech product, and the manufacturing of gene therapy products presents particular complications. KLOTHO is using AAVnerGene’s cutting-edge ‘ AAVone ‘ platform technology and engineered HEK293 cell line to introduce the plasmid DNA containing our Klotho gene, so that the AAV particles containing our gene are at a higher-than-normal titer concentration, have fewer impurities, and can be optimized and produced faster than the old standard method. We believe that working with AAVnerGene as our development partner has the potential to launch our product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current ‘triple transfection’ manufacturing method.”
One of the major challenges facing AAV-vectored gene therapies is the propensity of the AAVs to home in on the liver and induce an inflammatory response that causes life-threatening side effects and even death. AAVnerGene created a series of specific tissue-targeting AAVs developed with its ‘ ATHENA ‘ platform technology. Using the ATHENA system and tissue-specific targeting of the KLTO gene therapy product candidates containing KLTO’s tissue-specific promoters will be proven to be highly beneficial and likely safer than the AAV vectors that traffic to the liver.
AAVnerGene and Complexity of AAV-vectored Cell Lines
Over the past 20 years of gene therapy, investigators and companies used a process called “triple transfection” whereby three DNA plasmids are transfected, or inserted, into the cell line called HEK293. The three plasmids contain sequences of the ‘gene-of-interest’, Rep/Cap sequences from AAV and ‘Helper’ sequences from Adenovirus to provide essential viral genes to enable replication and packaging of the AAV. As the HEK293 cells replicate and produce the viral proteins, the HEK293 cells assemble the proteins required to make the AAV particles containing the gene-of-interest inside the AAV particle. This is a complicated, tedious, labor-intensive process requiring optimization that may take several months or a year to complete. AAVnerGene developed a one-plasmid AAV packaging system called ” AAVone, ” which dramatically increased the production efficiency, simplified the process, reduced the impurity, shortened the time and lowered the development cost.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO ) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. The Company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. KLOTHO is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications – Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com .
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
PR Newswire
Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators
NEW YORK , July 25, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (NASDAQ: KLTO ) (the “Company” or “Klotho”) announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.
“As announced previously, we’ve begun manufacturing and development of KLTO-101 and KLTO-202,” said Klotho CEO Dr. Joseph Sinkule . “We’re also exploring other treatments that could support healthy aging and extend human longevity.”
The human Klotho gene is strongly linked to aging and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.
“The Klotho gene is what we call a master gene,” stated Shalom Hirschman , M.D., world-renowned physician and senior consultant to the Company. “The Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two alpha-Klotho protein isoforms – soluble Klotho and secreted-Klotho.”
“We’re assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators,” said Jeffrey LeBlanc , Klotho CFO. “This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms.”
Dr. Sinkule added, “If people don’t die of cancer or trauma, they often succumb to age-related diseases of the brain, heart, kidneys, liver, bone, or muscle. Our mission is to identify and develop complementary assets to delay these outcomes through targeted research and intervention.”
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications – Jeffrey LeBlanc , CFO, ir@klothoneuro.com
Website: www.klothoneuro.com .
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
PR Newswire
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators
NEW YORK , July 24, 2025 /PRNewswire/ — Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the “Company” or “Klotho”) announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.
Klotho Neurosciences, Inc. logo (PRNewsfoto/Klotho Neurosciences, Inc.)
In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.
“As announced previously, we’ve begun manufacturing and clinical development of KLTO-101 and KLTO-202,” said Klotho CEO Dr. Joseph Sinkule . “We’re also exploring other treatments that could support healthy aging and extend human longevity.”
The human Klotho gene is strongly linked to aging and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.
“The Klotho gene is what we call a “master gene” stated Shalom Hirschman , M.D., world renowned physician and senior consultant to KLTO. Dr. Hirschman goes on to say “the Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two α-Klotho protein isoforms – soluble Klotho and secreted-Klotho.”
“We’re assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators,” said Jeffrey LeBlanc , Klotho CFO. “This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms.”
Dr. Sinkule added, “If people don’t die of cancer or trauma, they often succumb to age-related diseases of the brain, heart, kidneys, liver, bone, or muscle. Our mission is to identify and develop complementary assets to delay these outcomes through targeted research and intervention.”
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications – Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com .
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
PR Newswire
NEW YORK , July 22, 2025 /PRNewswire/ — Klotho Neurosciences, Inc . (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc . (AAVnerGene), a Rockville, MD -based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery.
KLOTHO NEUROSCIENCES, INC. – Gene and Cell Therapy of Longevity and Neurodegenerative Diseases.
Dr. Joseph Sinkule , the CEO of KLTO stated “we announced previously that we have been looking for a more efficient, ‘next-generation’ method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes. We are talking about KLTO-101 for Alzheimer’s and Parkinson’s diseases, KLTO-202 for ALS and other motor neuron diseases, and KLTO-303 for treatment of ageing-related pathologies resulting in a healthy, extended lifespan. I’m also looking at other complementary longevity -related assets that we may bring into KLTO.”
“AAV gene therapy has been proven to be a revolutionary one-time, life-changing treatment, however it is experiencing some crisis caused by high drug price and high dose-related toxicity,” said Dr. Daozhan Yu, Founder and CEO of AAVnerGene. “We envisioned these bottleneck problems six years ago and AAVnerGene was founded with the mission to solve them. With the two proprietary platforms, we can dramatically drive down the manufacture cost with the AAVone system and the dose required by the highly efficient and specific tissue-targeting AAVs developed with the ATHENA platform. It’s a perfect synergy to partner with Klotho, a neuroscience-driven pathfinder. Neurological disease drug development is always challenging and we need new approaches and mechanisms. Klotho’s data on neuron protection and longevity are very impressive and it holds the potential to treat so many devastating diseases. We are very glad to work with the passionate and highly executive team, and strongly believe that the collaboration can bring more affordable and innovative drugs for patients with rare and common diseases.”
Dr. Joseph Sinkule concluded “Klotho believes AAVnerGene has conceived a process method that is more cost effective, faster to make, has fewer impurities, shows higher efficacy and lower toxicity because of the higher targeted tissue delivery. KLTO hopes to work with AAVnerGene for manufacturing several of our product candidates composed of a tissue-specific promoter driving our Klotho gene to produce the Klotho protein and elevated concentrations of the protein in specific, targeted tissues and organs affected by these neurologic and neuromuscular diseases.”
About AAVnerGene, Inc . AAVnerGene is a creativity-powered biotechnology company pioneering next-generation AAV vector technologies. The company’s proprietary platforms include AAVone , a high-yield, single-plasmid AAV production system that dramatically reduces manufacturing costs, and ATHENA , an advanced capsid engineering platform enabling precise tissue targeting. AAVnerGene is dedicated to delivering affordable, scalable, and precision-engineered gene therapy solutions that accelerate clinical development across diverse therapeutic areas.
Investor Contact and Corporate Communications – Daozhan Yu, CEO
daozhan.yu@aavnergene.com
Website: www.aavnergene.com
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO ), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and it’s novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications – Jeffrey LeBlanc , CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
About Greenland Mines Ltd.
Greenland Mines Ltd. (Nasdaq: GRML) is a Charlotte, North Carolina-based company that, as of March 2026, controls one of the largest undeveloped palladium, gold, and platinum deposits on earth — the Skaergaard Project in Southeast Greenland. The company was formerly known as Klotho Neurosciences, Inc. and completed the acquisition of privately held Greenland Mines Corp. on March 4, 2026, simultaneously rebranding and beginning trading under the GRML ticker on March 12, 2026. Through that acquisition, the company holds an 80% interest in — and an option to acquire the remaining 20% of — the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 million ounces of palladium equivalent (PdEq) and 23.5 million ounces of gold equivalent (AuEq) across 364 million tonnes of mineralized rock. At February 2026 metal prices — gold near $3,000/oz, palladium at $1,800/oz, and platinum at $2,175/oz — the gross undiscounted in-situ resource value calculates to approximately $68 billion. The company’s current market capitalization is approximately $47 million.
The company now operates two divisions. The primary and defining division is Natural Resources, focused on the exploration and development of the Skaergaard Project. The secondary division is Cell and Gene Therapy, inherited from Klotho Neurosciences, which includes KLTO-202 — a gene therapy platform using a Klotho-based approach to treat ALS and other neurodegenerative diseases, along with a licensed generic drug portfolio and biosimilar biologics platform targeting cancer. The Skaergaard acquisition was structured as a reverse merger — Greenland Mines Corp. is expected to own approximately 93% of fully diluted shares on an as-converted basis — making this effectively a brand new company brought to market inside an existing Nasdaq shell. The Skaergaard Project has been studied since its discovery in 1935, with academic and institutional work conducted by Cambridge University, Caltech, and the Geological Survey of Denmark. More than $30 million has been invested in the project since the 1990s, and SLR Consulting completed a formal NI 43-101 Technical Report in 2022. The institutional awareness of the company under its new identity, however, is essentially zero: zero sell-side analysts cover the stock, and many data platforms still show the old company name.
The Skaergaard Resource: Scale, Composition, and Expansion Target
The numbers at Skaergaard are hard to contextualize at first read. The 2022 NI 43-101 resource of 25.4 million ounces PdEq and 23.5 million ounces AuEq is distributed across 364 million tonnes of rock — a deposit geometry that reflects the bulk, disseminated nature of mafic intrusion-hosted PGM-gold mineralization. The resource is approximately 73% platinum group metals (palladium and platinum) and 27% gold by value. Importantly, none of the $68 billion gross in-situ value figure accounts for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, or taxes — standard disclosure caveats that investors must take seriously. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed, and there is no certainty that mineral resources will be converted to mineral reserves or that an economically viable mining operation can be established. These are material risks that any investor must internalize before committing capital.
What Greenland Mines is targeting with its 2026 development program goes beyond simply confirming the existing resource. The company has identified geological targets it believes could double the contained resource to approximately 50 million ounces of gold, palladium, and platinum — expanding into areas of the Skaergaard Intrusion not fully captured in the 2022 estimate. Vanadium and gallium, both critical to defense electronics and next-generation energy storage, have also been identified within the broader Skaergaard mineralization and are being evaluated for potential inclusion in updated resource estimates. The appointment of GTK Mintec to handle metallurgical and processing flowsheet work — running in parallel with the geological work by SLR and the environmental baseline program by WSP — reflects the multi-disciplinary technical assembly that a project of this scale requires before any economic study can be initiated (Greenland Mines news releases, March–April 2026).
Geopolitical Context: Why Greenland, Why Now
The timing of Greenland Mines’ emergence as a public company cannot be separated from one of the most active geopolitical storylines of 2026: U.S. strategic interest in Greenland’s mineral wealth. The Trump administration’s public statements about acquiring Greenland — widely covered in late 2024 and throughout 2025 — reflect a deeper and more durable reality: Greenland sits at the intersection of the North Atlantic shipping corridor, is positioned between North America and Europe, and holds mineral resources that Western governments are actively seeking to secure outside of Chinese and Russian supply chains. Greenland’s government has aligned itself increasingly with Western mineral development interests, and its regulatory framework — administered through the Greenland Mineral Resources Act — is considered transparent and investor-friendly. There are no Chinese entanglements in the Skaergaard license, no third-party royalties encumbering the project, and the license holder is an Allied jurisdiction.
Bo Møller Stensgaard, who leads the Natural Resources division as President, has spent more than 25 years working in Greenland geology, beginning his career with the Geological Survey of Denmark and Greenland in 1998. He was the first scientist to assess a Greenland area using combined geological, geophysical, and geochemical datasets — a methodological integration that is now standard practice — and he has noted that Greenland’s surface exposure of mineralization makes it an unusually accessible geological environment compared to most exploration frontiers. His description of Greenland as “an open textbook and a natural laboratory for geology” reflects both his technical affinity for the island and his conviction that the Skaergaard deposit’s surface accessibility is a meaningful development advantage relative to deeply buried or structurally complex deposits in other jurisdictions (InvestorNews, April 2026).
2026 Field Season: What Is Actually Happening on the Ground
The 2026 field season at Skaergaard is the first concrete development activity under Greenland Mines’ ownership, and the company has moved decisively to assemble the infrastructure required to execute it. The most operationally significant announcement to date is the chartering of M/V Argus — a dedicated Arctic icebreaker with Class A1 Super ice capability, accommodation for 40–50 personnel, a certified helicopter deck, and aviation fuel storage — from IceTugs ApS for the full duration of the field campaign. The vessel will serve as the primary offshore logistics hub, transporting drill rigs, supplies, fuel, and personnel from Reykjavík, Iceland, to Mikis Fjord adjacent to the Skaergaard site, and integrating helicopter operations directly from the ship to access the surrounding project area. Securing M/V Argus is not a trivial logistical accomplishment: President Stensgaard noted that there are very few vessels of comparable ice class, capacity, and Arctic track record available in the North Atlantic, and competition from scientific and commercial operators is intense (Greenland Mines News Release, March 26, 2026).
On the technical side, SLR Consulting — engaged April 27, 2026, as geological consultant and Qualified Person — brings critical continuity: SLR prepared the 2022 NI 43-101 and already has detailed knowledge of the Skaergaard geological model and existing resource. SLR’s scope covers resource definition, drill and bulk-sample planning, mine planning, metallurgy, and processing flowsheet work, with a site visit planned for late August or early September 2026. WSP Danmark A/S is concurrently advancing the Environmental Impact Assessment baseline program — covering environmental, biological, and hydrological surveys across the project area — which is a prerequisite for the exploitation license application. GTK Mintec is leading metallurgical and processing flowsheet and pilot test work. The combination of SLR, WSP, and GTK Mintec constitutes an unusually capable and experienced advisory team for a company at GRML’s current market capitalization.
EXCHANGE:
NASDAQ
Symbol: GRML
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decisions. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc.
While the information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful; investing in securities carries a high degree of risk; you may likely lose some or all of your investment.
ABOUT US
Equity Insider offers news and information from global equity markets. We focus on emerging markets, along with hot topics and timely business news.
CONTACT US
Equity Insider
- support@equity-insider.com
- www.equity-insider.com
©Copyright 2025 Equity-Insider.com. All Rights Reserved